Eli Lilly ROA 2006-2018 | LLY

Current and historical return on assets (ROA) values for Eli Lilly (LLY) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Eli Lilly ROA for the three months ending September 30, 2018 was 12.64%.
Eli Lilly ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-09-30 $0.45B $44.63B 1.02%
2018-06-30 $-0.14B $42.36B -0.33%
2018-03-31 $1.12B $44.36B 2.59%
2017-12-31 $-0.20B $44.98B -0.49%
2017-09-30 $2.23B $43.01B 5.55%
2017-06-30 $2.45B $40.95B 6.32%
2017-03-31 $2.19B $37.62B 5.81%
2016-12-31 $2.74B $38.81B 7.42%
2016-09-30 $2.44B $37.59B 6.77%
2016-06-30 $2.47B $36.48B 6.90%
2016-03-31 $2.32B $34.69B 6.50%
2015-12-31 $2.41B $35.57B 6.71%
2015-09-30 $2.36B $36.31B 6.54%
2015-06-30 $2.06B $36.04B 5.78%
2015-03-31 $2.19B $35.65B 6.20%
2014-12-31 $2.39B $36.31B 6.80%
2014-09-30 $2.69B $34.65B 7.70%
2014-06-30 $3.39B $35.02B 9.76%
2014-03-31 $3.86B $34.76B 11.27%
2013-12-31 $4.68B $35.25B 13.91%
2013-09-30 $4.78B $33.97B 14.29%
2013-06-30 $4.91B $33.23B 14.62%
2013-03-31 $4.63B $32.30B 13.93%
2012-12-31 $4.09B $34.40B 12.32%
2012-09-30 $4.12B $34.32B 12.48%
2012-06-30 $4.03B $31.81B 12.33%
2012-03-31 $4.30B $32.24B 13.06%
2011-12-31 $4.35B $33.66B 13.26%
2011-09-30 $4.66B $33.04B 14.50%
2011-06-30 $4.73B $32.78B 15.08%
2011-03-31 $4.88B $31.70B 16.22%
2010-12-31 $5.07B $31.00B 17.51%
2010-09-30 $4.82B $29.90B 17.15%
2010-06-30 $4.45B $27.72B 16.27%
2010-03-31 $4.26B $27.20B 15.69%
2009-12-31 $4.33B $27.46B 16.02%
2009-09-30 $-0.22B $27.13B -0.78%
2009-06-30 $-1.62B $26.93B -5.88%
2009-03-31 $-1.82B $26.60B -6.55%
2008-12-31 $-2.07B $29.21B -7.41%
2008-09-30 $2.41B $27.71B 8.80%
2008-06-30 $3.80B $27.75B 14.24%
2008-03-31 $3.51B $27.22B 13.61%
2007-12-31 $2.95B $26.88B 11.85%
2007-09-30 $2.23B $24.97B 9.42%
2007-06-30 $2.18B $24.06B 9.31%
2007-03-31 $2.34B $23.73B 9.94%
2006-12-31 $2.66B $21.96B 11.28%
2006-09-30 $3.23B $23.91B 13.32%
2006-06-30 $3.15B $24.44B 12.87%
2006-03-31 $2.08B $24.15B 8.57%
2005-12-31 $1.98B $24.58B 8.25%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $120.858B $22.871B
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $389.718B 18.27
Pfizer (PFE) United States $264.307B 14.90
Merck (MRK) United States $208.739B 18.09
Novartis AG (NVS) Switzerland $200.739B 17.21
AbbVie (ABBV) United States $131.784B 11.70
Novo Nordisk (NVO) Denmark $112.280B 18.23
Sanofi (SNY) France $110.782B 13.72
AstraZeneca (AZN) United Kingdom $97.289B 12.08
GlaxoSmithKline (GSK) United Kingdom $93.444B 12.56
Bristol-Myers Squibb (BMY) United States $85.821B 14.13